Showing 6601-6610 of 10478 results for "".
- Cybersecurity Firm Offers Tips to Protect Dermatology Practice Datahttps://practicaldermatology.com/news/cybersecurity-firm-offers-tips-to-protect-dermatology-practice-data/2461029/Ransomware attacks continue to target the healthcare sector. Black Talon Security, a leading NY-based national cybersecurity firm, offers 10 tips that all dermatology practices should follow to keep data secure and protect patient r
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory p
- The American Skin Association Re-ups Support for the SPOTS Programhttps://practicaldermatology.com/news/the-american-skin-association-re-ups-support-for-the-spots-program/2461023/The American Skin Association (ASA) is renewing its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a public health outreach educational program aimed at both elementary school students and young teenagers. The comprehensive pr
- Dermatologist Tackles Misinformation Related to COVID-19 Vaccines and Injectable Fillers and Toxinxhttps://practicaldermatology.com/news/dermatologist-tackles-misinformation-related-to-covid-19-vaccines-and-injectable-fillers/2461022/With a recent article in the Wall Street Journal article suggesting that patients must choose between neurotoxin treatments or COVID-19 vaccines, dermatologists are scurrying to set the record straight. While there have been rare reports of non-life-threatening, transient reactions
- LEO Pharma's Adbry Approved for Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-approved-for-moderate-to-severe-ad/2461020/FDA has approved Adbry™ (tralokinumab-ldrm) from LEO Pharma Inc. for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the
- Obagi Enters Device Arena with The Skintrinsiq Systemhttps://practicaldermatology.com/news/obagi-enters-device-arena-with-the-skintrinsiq-system/2461019/Obagi is launching the Skintrinsiq device, its first entry into the complementary skincare device market. The Skintrinsiq system extracts impurities then infuses Obagi skincare products via treatment protocols customized for individual skincare needs. "The uni
- Tremfya Five-Year Data Show No New Safety Signalshttps://practicaldermatology.com/news/tremfya-five-year-data-show-no-new-safety-signs/2461016/New data published in the
- FDA Accepts sNDA for Incyte's Opzelura for Vitiligohttps://practicaldermatology.com/news/fda-accepts-snda-for-incytes-opzelura-for-vitiligo/2461009/FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAK inhibitor from Incyte, as a potential treatment for adolescents and adults with vitiligo. The sNDA is supported by data from the Phase 3 TRuE-V cl
- FDA Approves Higher Dilution in New Sculptra Labelhttps://practicaldermatology.com/news/fda-approves-higher-dilution-in-new-sculptra-label/2461007/A new FDA-approved label for Sculptra® (injectable poly-L-lactic acid (PLLA)) from Galderma includes higher dilution, the addition of immediate use reconstitution, new injection techniques, and the optional addition of lidocaine. Sculptra is the first and only FDA-approved PLLA facial in